Selective serotonin re-uptake inhibitor sertraline inhibits bone healing in a calvarial defect model

Abstract

Bone wound healing is a highly dynamic and precisely controlled process through which damaged bone undergoes repair and complete regeneration. External factors can alter this process, leading to delayed or failed bone wound healing. The findings of recent studies suggest that the use of selective serotonin reuptake inhibitors (SSRIs) can reduce bone mass, precipitate osteoporotic fractures and increase the rate of dental implant failure. With 10% of Americans prescribed antidepressants, the potential of SSRIs to impair bone healing may adversely affect millions of patients’ ability to heal after sustaining trauma. Here, we investigate the effect of the SSRI sertraline on bone healing through pre-treatment with (10 mg·kg^-1 sertraline in drinking water, n = 26) or without (control, n = 30) SSRI followed by the creation of a 5-mm calvarial defect. Animals were randomized into three surgical groups: (a) empty/sham, (b) implanted with a DermaMatrix scaffold soak-loaded with sterile PBS or (c) DermaMatrix soak-loaded with 542.5 ng BMP2. SSRI exposure continued until sacrifice in the exposed groups at 4 weeks after surgery. Sertraline exposure resulted in decreased bone healing with significant decreases in trabecular thickness, trabecular number and osteoclast dysfunction while significantly increasing mature collagen fiber formation. These findings indicate that sertraline exposure can impair bone wound healing through disruption of bone repair and regeneration while promoting or defaulting to scar formation within the defect site.

References

[1] Pratt, L. A., Brody, D. J. & Gu, Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 76 1–8 (2011).

[2] Diem SJ, . Use of antidepressant medications and risk of fracture in older women. Calcif. Tissue Int., 2011, 88: 476-484.

[3] Gu B, Wu G, Si J, Xu Y, Andersson KE. Improving voiding efficiency in the diabetic rat by a 5-HT1A serotonin receptor agonist. Neurourol. Urodyn., 2012, 31: 168-173.

[4] Gagne JJ, Patrick AR, Mogun H, Solomon DH. Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin. Pharmacol. Ther., 2011, 89: 880-887.

[5] Bruyere O, . Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX) to assess the 10-year probability of fracture. Rheumatol. Int., 2013, 33: 979-983.

[6] Okazaki R. Fracture risk associated with drugs other than glucocorticoids. Clin. Calcium, 2014, 24: 357-365.

[7] Moberg LM, Nilsson PM, Samsioe G, Borgfeldt C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas, 2014, 78: 310-315.

[8] Gold PW, . Chronic administration of anticonvulsants but not antidepressants impairs bone strength: clinical implications. Transl. Psychiatry, 2015, 5

[9] Diem SJ, . Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J. Clin. Endocrinol. Metab., 2014, 99: E1732-E1737.

[10] Lanteigne A, . Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older. CNS Drugs, 2015, 29: 245-252.

[11] Shea ML, . Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption. Osteoporos. Int., 2013, 24: 1741-1749.

[12] Rabenda V, Nicolet D, Beaudart C, Bruyere O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos. Int., 2013, 24: 121-137.

[13] Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos. Int., 2012, 23: 365-375.

[14] Sheu YH, . SSRI use and risk of fractures among perimenopausal women without mental disorders. Inj. Prev., 2015, 21: 397-403.

[15] Bradaschia-Correa V, . The selective serotonin reuptake inhibitor fluoxetine directly inhibits osteoblast differentiation and mineralization during fracture healing in mice. J. Bone Miner. Res., 2017, 32: 821-833.

[16] Karsenty G, Yadav VK. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu. Rev. Med., 2011, 62: 323-331.

[17] Hodge JM, . Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol. Psychiatry, 2013, 74: 32-39.

[18] Salai M, . Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study. Bone Jt. J., 2013, 95-B: 1575-1580.

[19] Cray JJ Jr., . Selective serotonin reuptake inhibitor exposure alters osteoblast gene expression and craniofacial development in mice. Birth Defects Res. A Clin. Mol. Teratol., 2014, 100: 912-923.

[20] Burt, C. W. & Fingerhut, L. A. Injury visits to hospital emergency departments: United States, 1992-95. Vital Health Stat. 13 131, 1–76 (1998).

[21] Mitchener TA, Canham-Chervak M. Oral-maxillofacial injury surveillance in the Department of Defense, 1996-2005. Am. J. Prev. Med., 2010, 38: S86-S93.

[22] Katz RV, Barnes GP, Larson HR, Lyon TC, Brunner DG. Epidemiologic survey of accidental dentofacial injuries among U.S. Army personnel. Community Dent. Oral. Epidemiol., 1979, 7: 30-36.

[23] Snowden CB, Miller TR, Jensen AF, Lawrence BA. Costs of medically treated craniofacial conditions. Public Health Rep., 2003, 118: 10-17.

[24] Wan DC, Nacamuli RP, Longaker MT. Craniofacial bone tissue engineering. Dent. Clin. North Am., 2006, 50: 175-190. vii

[25] Cho YR, Gosain AK. Biomaterials in craniofacial reconstruction. Clin. Plast. Surg., 2004, 31: 377-385. v

[26] Wu X, . Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failure: a cohort study. J. Dent. Res., 2014, 93: 1054-1061.

[27] Gaviria L, Salcido JP, Guda T, Ong JL. Current trends in dental implants. J. Korean Assoc. Oral. Maxillofac. Surg., 2014, 40: 50-60.

[28] American Association of Oral and Maxillofacial Surgeons. Oral and Maxillofacial Surgerons: The Experts in Face, Mouth and Jaw Surgery, 2014 IL Rosemount

[29] Herberg S, . Mesenchymal stem cell expression of SDF-1beta synergizes with BMP-2 to augment cell-mediated healing of critical-sized mouse calvarial defects. J. Tissue Eng. Regen. Med., 2017, 11: 1806-1819.

[30] Herberg S, . Inkjet-based biopatterning of SDF-1beta augments BMP-2-induced repair of critical size calvarial bone defects in mice. Bone, 2014, 67: 95-103.

[31] Cooper GM, . Testing the critical size in calvarial bone defects: revisiting the concept of a critical-size defect. Plast. Reconstr. Surg., 2010, 125: 1685-1692.

[32] Ortuno MJ, . Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat. Med., 2016, 22: 1170-1179.

[33] Allport J. Incidence and prevalence of medication-induced osteoporosis: evidence-based review. Curr. Opin. Rheumatol., 2008, 20: 435-441.

[34] Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging, 1998, 12: 43-53.

[35] Haney EM, . Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med., 2007, 167: 1246-1251.

[36] Richards JB, . Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med., 2007, 167: 188-194.

[37] Williams LJ, . Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Psychopharmacol., 2008, 23: 84-87.

[38] Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch. Biochem. Biophys., 2008, 473: 231-236.

[39] Zofkova I, Matucha P. New insights into the physiology of bone regulation: the role of neurohormones. Physiol. Res., 2014, 63: 421-427.

[40] Johnson ML. LRP5 and bone mass regulation: where are we now?. Bone Rep., 2012, 1: 1.

[41] Kubota T, Michigami T, Ozono K. Wnt signaling in bone. Clin. Pediatr. Endocrinol., 2010, 19: 49-56.

[42] Yadav VK, Ducy P. Lrp5 and bone formation: a serotonin-dependent pathway. Ann. N. Y. Acad. Sci., 2010, 1192: 103-109.

[43] Zhang W, Drake MT. Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis. Curr. Osteoporos. Rep., 2012, 10: 93-100.

[44] Hu YF, Caron MG, Sieber-Blum M. Norepinephrine transport-mediated gene expression in noradrenergic neurogenesis. BMC Genomics, 2009, 10

[45] Zuo C, . Osteoblastogenesis regulation signals in bone remodeling. Osteoporos. Int., 2012, 23: 1653-1663.

[46] Agnihotri N, Mehta K. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target. Amino Acids, 2017, 49: 425-439.

[47] Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr. Opin. Endocrinol. Diabetes Obes., 2013, 20: 14-21.

[48] Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol., 2010, 8: e1000412.

[49] Bouxsein ML, . Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res., 2010, 25: 1468-1486.

[50] Varghese F, Bukhari AB, Malhotra R, De A. IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE, 2014, 9: e96801.

[51] Durham EL, . Effects of thyroxine exposure on the Twist 1+/- phenotype: a test of gene-environment interaction modeling for craniosynostosis. Birth. Defects Res. A Clin. Mol. Teratol., 2016, 106: 803-813.

[52] Zhang W, . Age-related changes in the osteogenic differentiation potential of mouse bone marrow stromal cells. J. Bone Miner. Res., 2008, 23: 1118-1128.

[53] NIH. Toxicology Data Network: Sertraline (National Library of Medicine HSDB Database, Bethesda, MD, 2002).

[54] Yuan JS, Reed A, Chen F, Stewart CN Jr.. Statistical analysis of real-time PCR data. BMC Bioinforma., 2006, 7